Category: Vaccine

Page 152«..1020..151152153154..160170..»

Jonas Salk, the man who cured polio, would have been baffled by modern anti-vaxxers, experts say – Salon

November 2, 2023

Polio is a highly infectious viral disease that invades the nervous system and can trigger total paralysis in a matter of hours. It mainly targets children under age 5, and at one time disabled and killed thousands of American children every year. Today, all that is a distant memory. The World Health Organization recently estimated that, thanks to polio vaccines, "More than 20 million people are able to walk today who would otherwise have been paralyzed. An estimated 1.5 million childhood deaths have been prevented through the systematic administration of vitamin A during polio immunization activities."

That breakthrough was largely the work of Dr. Jonas Salk, the American virologist who developed one of the first polio vaccines. A year before Salk died in 1995, polio was considered eradicated in North and South America and today cases have decreased by 99% globally. There were just six cases reported in 2021.

In 1955, when Salk was close to announcing his vaccine was successful, he famously said he didn't believe it would be right for any individual to patent such an essential drug. After being asked to explain who owned the vaccine, Salk stated that "the people" were the owners, justifying that fact with a famous rhetorical question: "Could you patent the sun?"

It was an iconic moment in the history of public health, particularly in an era whenvaccine inequity makes it difficult for millions to receive life-saving inoculations. Perhaps it is even more so in the COVID-19 era, when anti-vaccine ideology has become a badge of identity for millions of conservatives.

"His liberality ended up with him being investigated by [FBI Director] J. Edgar Hoover at one point."

Yet the talk of Salk's wisdom is more complicated than it may first appear. As Stanford professor and Salk biographer Dr. Charlotte D. Jacobs told Salon by email, Salk's explanation has caused subsequent scholars to mistakenly claim that he personally gave away the polio vaccine which he never owned in the first place. Salk was acknowledging the work of his many predecessor scientists, as well as expressing his individual belief that such drugs should be widely available.

Salk's work "was supported by the National Foundation for Infantile Paralysis, better known as the March of Dimes," Jacobs told Salon by email. "Its director, Basil O'Connor, made it clear to all scientists that the foundation prohibited patents for all work performed under its research grants."

At the same time, Salk was a prominent liberal who cared about public health and believed that quality medical care should be widely available. As his son, Dr. Peter Salk of the University of Pittsburgh's School of Public Health, told Salon, there are lessons from his life that clearly apply to present conditions. Salk had no desire to become rich from his work, his son said, a stark contrast to the current era when most new drugs are developed by pharmaceutical companies frequently accused of exploiting public health needs,predatory pricing, misleading marketingand deliberatelystalling vaccine development to protect corporate profits.

"My father absolutely did not have any interest personally in in the vaccine being patented," Salk told Salon. Even after the March of Dimes hired an attorney to explore patenting the polio vaccine (which was unsuccessful), he said, "the thing that struck me was my father's absolute disinterest in getting together with that patent attorney. It was very rather frustrating for the attorney because my father was completely focused on the work that was in front of him."

There is another lesson in Salk's example namely, his assumption that the public would almost unanimously welcome vaccines. This may be difficult to believe in our increasingly contentious era, but America in the '50s and '60s had no widespread anti-vaccine movement. Vaccines were viewed as a remarkable innovation that could save millions of lives by preventing potentially deadly diseases.

Salk "would be shocked" by the rise of the contemporary anti-vaccine movement, said Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia. "He grew up at a time when diphtheria was a routine killer of teenagers and whooping cough would kill 8,000 to 10,000 people a year. Polio would paralyze 30,000 to 35,000 people a year and kill 1,500 people."

Remembering his own 1950s childhood, Offit said that his parents were terrified of polio and that his mother cried with joy when the polio vaccine was announced.

Want more health and science stories in your inbox? Subscribe to Salon's weekly newsletter Lab Notes.

"My father absolutely just did not have any interest personally in patenting and in the vaccine being patented."

"We saw vaccines for what they were, which were lifesavers," Offit said. "We didn't have this sort of level of distrust and division that we have today."

He cited the "Cutter incident" of 1955 as a "perfect example" of this widespread public trust in science. A private lab that was commissioned to mass-produce copies of Salk's vaccine accidentally sent out versions containing a live polio virus. Roughly 40,000 children developed active cases of polio, at least 200 were permanently paralyzed and 10 died. That disastrous outcome could certainly have shaken public confidence in vaccines but that's not what happened

The Cutter incident "demonstrated the need for the U.S. government to take a stronger regulatory role in approving new vaccines,"Dr. Daniel Wilson, a retired history professor at Muhlenberg College and author of "Living with Polio: The Epidemic and Its Survivors," told Salon in 2021. "It may also have helped move the government to more strongly finance medical and scientific research. Remember, the polio research and trials for theSalk and Sabin vaccineswere almost entirely funded by the private philanthropy [of] the March of Dimes."

"I think it was probably the worst biological disaster in this country's history," Offit said, "and it in no sense had shaken the trust that people had in the government and the pharmaceutical industry and vaccine regulation. Not at all. If you looked at the exit interviews from those people who were jurors in the first trials, they trusted the companies.They saw what it was: a process of evolution."

Dr. Peter Salk said his father would be "really puzzled" by the emergence and spread of anti-vaccine ideology. "His whole commitment was protecting the population from infectious diseases," which did not stop him from also caring about "problems confronting humanity that were outside of the realm of infectious disease and physical illness." Peter Salk mentioned the books his father wrote later in life, including "World Population and Human Values: A New Reality" in 1981 and "Anatomy of Reality: Merging of Intuition and Reason" in 1983."He was absolutely committed to the notion that humanity needs to do something to change their way of thinking and behaving if we're going make it through this transition the period that we're still struggling with," Peter Salk added.

He added that in Jonas Salk's final years, he worked on efforts to develop an HIV vaccine. Although that was not successful, Salk said that his father was "deeply engaged in introducing HIV treatment programs in Africa and Asia, highly aware of the inequities and involved in the whole system [of improving] access to medications." and so on.

Salk's liberal politics meant that despite his undoubted scientific credentials, he became the focus of an investigation by legendary FBI Director J. Edgar Hoover, Peter Salk said. "They didn't come up with anything."

Read more

about pandemics

Follow this link:

Jonas Salk, the man who cured polio, would have been baffled by modern anti-vaxxers, experts say - Salon

Former MoMA Worker Sues Museum Over COVID Vaccine Exemption – Hyperallergic

November 2, 2023

A former employee of the Museum of Modern Art (MoMA) in New York is suing the arts institution and three of its employees, accusing the museum of disability discrimination and unlawful termination for allegedly failing to accommodate his vaccine exemption request.

First reported by Law360, the suit was filed in New Yorks Southern District Court last Thursday, October 26, by Philip Parente, who spent 17 years working in the museums library and archive collections. He was terminated from his position as MoMAs library collections coordinator in November 2021 after refusing to take the COVID-19 vaccine as mandated by an on-site work policy implemented during the pandemic, citing a cardiac condition. Some studies have documented infrequent cases of cardiac events following COVID-19 immunization, though scientists generally agree that the benefits of vaccination outweigh these minor cardiac risks.

MoMA has not yet responded to Hyperallergics requests for comment.

According to the lawsuit, Parente began seeing New York doctor Patrick Fratellone in 2011 for a condition known as supraventricular tachycardia that causes a rapid heartbeat, and Fratellone advised him not to take the COVID-19 vaccine. The former employee sought a medical exemption request for accommodation on September 10, 2021, according to the filing. MoMA denied this request on September 13, noting in an email, Without assessing whether your medical condition actually prohibits vaccination, we are unable to accommodate your request to work at MoMA while unvaccinated.

Parente was subsequently placed on 30-day unpaid leave and threatened with termination, as the essential functions of [his] job required him to be physically present at the museum.

Parente claims that the exemption denial represents a violation of federal and state protections for workers with disabilities, including theAmericans with Disabilities Act of 1990, and alleges that he was subjected to discriminatory and retaliatory conduct from the museum higher-ups and staff. When he met with human resource representatives to discuss his request for accommodation, Parente claims, they accused him of stealing from the museum based on a previous request he had made for baby wipes and photo negatives for a personal photography project.

The filing also alleges that the museums chief human resources officer described his contributions to MoMA which included curating a photography installation for the education center and acquiring new materials for the library as insignificant.

When Parente supplied MoMA with information from Fratellone on October 1 to contextualize his request, the museum again rejected his accommodation request on the basis that the medical advice is contrary to the latest guidance from the CDC and does not appear to provide the basis for an accommodation. The museum also invoked then-Mayor Bill de Blasios Keys to NYC COVID-19 vaccination mandate for public indoor establishments including cultural venues.

In a last effort, Parente reached out to his managerfor a vaccine exemption, this time reasoning that since the museum closed to the public in March 2020, he had been able to perform the vast majority of [his] typical daily workload from home. However, he says he received no response,but thathis email was reportedly passed on to the museums legal counsel and other staff. The suit details that when Parente met again with museum staff, he suggested a compromise that would allow him to work on-site in an unoccupied room on a different floor from collections staff. This alternative was also allegedly dismissed, and Parente was later terminated in November 2021.

In this work environment at MoMA, regardless of what your doctor says, MoMA apparently believes they have the last word. My client was a long-term patient of his cardiologist and did not just come up with a feigned illness to avoid MoMAs newly implemented and ultimately unsuccessful COVID-19 policy, Christopher Berlingieri, Parentes legal representative, told Hyperallergic.

See the article here:

Former MoMA Worker Sues Museum Over COVID Vaccine Exemption - Hyperallergic

‘Nobody wants to speak about COVID’: Less than 3% of eligible Americans got a booster shot in September does … – Yahoo Finance

November 2, 2023

Nobody wants to speak about COVID: Less than 3% of eligible Americans got a booster shot in September does that spell trouble for these 3 big vaccine stocks?

From pandemic fatigue to vaccine fatigue Americans are proving slow to follow the CDCs advice to get a COVID-19 booster shot this fall.

On Sept. 12, the CDC recommended that everyone six months and older should get an updated COVID-19 vaccine to protect against the potentially serious outcomes of the illness as we roll into the winter months.

But by the end of September, only 7.6 million people, or less than 3% of eligible Americans, had rolled up their sleeves and received the updated shots, according to Reuters.

Most Americans can still get a COVID-19 vaccine for free either through their health insurance plan or via local health centers and certain pharmacies. Despite that, uptake of the current fall/winter booster has so far been extremely low, according to the CDC release. This is in part due in part to some finding it difficult to book vaccination appointments or find booster shots at no cost.

Low uptake of the booster shots is concerning for not only the countrys health care leaders, but also for the companies that make the COVID-19 vaccines and the investors who added them to their stock portfolios

Heres a look at how the big three vaccine makers are coping with the lower-than-expected demand this fall.

Pfizer recently slashed its full-year revenue outlook for 2023 to $58 billion to $61 billion down from its previous estimate of $67 billion to $70 billion solely due to COVID products.

Amidst poor vaccination uptake this fall, the pharmaceutical giant now expects sales of its COVID-19 vaccine, Comirnaty, to be $2 billion lower than previously expected in 2023. It has also slashed its expected Paxlovid (anti-virus medication used as treatment for COVID) revenues by approximately $7 billion.

Story continues

We are in the middle of the Covid fatigue, said Pfizer CEO Albert Bourla during an investor call on Oct. 16. Nobody wants to speak about Covid. We have the big anti-vaccination rhetoric.

Facing such uncertainty, Pfizer cut its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share a far cry from the prior estimate of $3.25 to $3.45 per share causing its stock to tumble.

But Pfizer stock recovered quickly after Bourla explained the companys cost realignment program, which will include layoffs and is expected to deliver savings of $1 billion this year and an additional $2.5 billion in 2024.

Like two peas in a pod, when Pfizer slashed its full-year outlook, investors immediately started to worry about Modernas 2023 prospects and its stock value slumped. And unlike its main competitor, Moderna shares did not see a quick recovery.

In August, Moderna reported total revenue for the second quarter of $344 million, compared to $4.7 billion in the same period in 2022 mainly due to a decrease in sales of the companys COVID-19 vaccine.

The company which is expected to report its third quarter earnings on Nov. 2 reported $0.3 billion in COVID-19 vaccine sales in the second quarter and $2.1 billion for the first half of the year, hitting its expectations.

We are on track to deliver 2023 [COVID-19 vaccine] sales between $6 billion to $8 billion, depending on Covid vaccination rates in the U.S., said Moderna CEO Stphane Bancel, when announcing the latest results.

Read more: Thanks to Jeff Bezos, you can now use $100 to cash in on prime real estate without the headache of being a landlord. Here's how

Moderna has so far retained that guidance despite Pfizers revision in October, according to Investors Business Daily (IBD), stating that its projection reflects the uncertainty of U.S. vaccination rates.

In the second quarter, Moderna reported a loss per share of $3.62, compared to a year-earlier gain of $5.24 per share. IBD reported that analysts expect that loss trend to continue in the third quarter.

Novavax is another vaccine maker that felt the sting of Pfizers $9 billion projected revenue slash. Novavax shares dropped by 4.5% shortly after Pfizers announcement, adding fuel to the uncertainty around the vaccine companys financial future after it cut its 2023 outlook in August.

Despite beating expectations in the second quarter of this year scoring $424 million in revenue and earning 65 cents per share Novavax reduced its expected total 2023 product sales to $960 million to $1.14 billion, down from its previous estimate of $1.06 billion to $1.24 billion.

The Novavax vaccine is unique in that it is the only non-mRNA protein-based XBB COVID vaccine available in the U.S. and therefore appeals to a section of the population that is uneasy over mRNA technology.

Novavax received the Food and Drug Administration (FDA)s go-ahead for its updated COVID shot on Oct. 3, but it was only approved for individuals aged 12 and older setting the drug giant at a potential disadvantage to Pfizer and Moderna, whose updated vaccines are suitable for those as young as six months old.

On Oct. 16, the company released a statement expressing its confidence in the ongoing rollout and broad availability of its vaccine in the U.S. market.

Following arrival in pharmacies and health care provider offices, and first doses administered last week, Novavaxs vaccine is now widely available throughout the U.S. Novavax believes it is too soon to evaluate U.S. vaccination rates given that vaccinations will continue in the coming weeks.

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.

More:

'Nobody wants to speak about COVID': Less than 3% of eligible Americans got a booster shot in September does ... - Yahoo Finance

Report shows few opting to get new COVID-19 vaccine – WKRC TV Cincinnati

November 2, 2023

Report shows few opting to get new COVID-19 vaccine

by Liz Bonis & Megan Burgasser, WKRC

(File)

CINCINNATI (WKRC) - A new report shows few people are choosing to get the new COVID-19 vaccine.

After just about a month, new numbers presented to the Centers for Disease Control and Prevention show many people appear to be hesitant when it comes to getting the new COVID-19 vaccine.

A national survey of thousands of Americans conducted just a few weeks ago asked families who has had the COVID-19 vaccine.

Only 7% of adults and 2% of children have gotten the shot, according to researchers. 40% of adults said they likely wont get it or give it to their kids.

Renee Mahaffey Harris, of the Center for Closing the Health Gap, said hesitancy is especially high among Black and brown people.

I think the ongoing hesitancy within the Black community and other populations goes back to long-term distrust, said Mahaffey Harris, president and CEO of the Center for Closing the Health Gap. But the more you can encourage and provide information that is provided by organizations that represent the populations, thats where we are beginning to see a greater understanding of the why.

The new vaccine is recommended for all Americans six months and older. Doctors are especially concerned that the upcoming holiday travel season will lead to another spike in the illness, due to newer variants circulating the globe.

While many are asking why they should get the new vaccine, because people can still get infected even afterward, infectious disease specialists remind everyone that the vaccine does well at protecting against the odds a person can get seriously ill from it.

The newer omicron variants are very transmissible, and we are seeing lots of younger people who are getting it, and its still going around our community. So, I dont expect a decline, I expect an increase, said Dr. Carl Fichtenbaum, an infectious disease researcher in the UC College of Medicine.

Load more...

Read more:

Report shows few opting to get new COVID-19 vaccine - WKRC TV Cincinnati

Plane-dropped bait vaccinates raccoons in the eastern U.S. : Short Wave – NPR

November 2, 2023

The United States Department of Agriculture's rabies management program includes delivering oral vaccines to raccoons by plane, helicopter and vehicle to control the spread of rabies. Johannes Eisele/AFP via Getty Images hide caption

The United States Department of Agriculture's rabies management program includes delivering oral vaccines to raccoons by plane, helicopter and vehicle to control the spread of rabies.

In the early 1900s, more than 100 people died annually from rabies in the United States.

These days, that number is five or less.

And although hundreds of domestic animals and livestock still contract the disease every year, their numbers were historically much higher too. All species of mammals are susceptible to rabies infections. But only a few of those species act as reservoirs, or hosts that allow the virus to spread.

And so, since 1995, the U.S. Department of Agriculture has run a yearly campaign that aims to keep rabies at bay in one population in particular: raccoons.

How they vaccinate is somewhat unique.

Every year, the USDA drops millions of oral rabies vaccines across fourteen states, mostly along the eastern seaboard. (Texas also has a program.) In urban and suburban areas, this usually means officials drive around, depositing bait where raccoons are likely to find it and eat it, like around dumpsters.

In rural areas, though, there's a more efficient way to distribute the bait.

"They're scattered by these low flying planes. And the planes have a tube and a conveyor belt that just drops these vaccines to make sure they're sort of evenly dispersed," says Emily Mullin, a staff writer for WIRED who covered the USDA raccoon vaccination program.

The program covers tens of thousands of square miles. So far, the program has been a big success. It has essentially stopping the geographic spread of rabies in the eastern U.S., according to Jordona Kirby, a USDA wildlife biologist and field coordinator for the National Rabies Management Program.

Long term, she hopes the program will stomp out raccoon rabies for good. That would require "marching it from its current extent, which is essentially along the Appalachian Mountains running from Maine to Alabama ... all the way back to the ocean," she says. "That is our long term vision."

The oral rabies vaccine was developed in the 1960s and '70s. The first field trials targeted red foxes in Switzerland.

By the 1990s, the U.S. began its first field trial on an uninhabited Atlantic barrier island off the coast of Virginia. And in the mid '90s, the USDA started partnering with states to begin oral rabies vaccination programs for wildlife.

One key to the success of the raccoon vaccination effort was making the bait palatable to a raccoon. "So we've got the fish flavor and then the other one is a sweet flavor ... both of which work quite well for raccoons," says Kirby.

Turns out, raccoons love a vanilla oral vaccine. Go figure!

A USDA employee loads oral rabies vaccine baits onto a helicopter as the crew and pilot prepare to distribute them in suburban areas. USDA hide caption

A USDA employee loads oral rabies vaccine baits onto a helicopter as the crew and pilot prepare to distribute them in suburban areas.

But these flavors don't only attract raccoons. "Our feelings are absolutely not hurt if skunks, foxes or coyotes pick them up. And they do," Kirby notes. "So, although raccoons are the reservoir and spread rabies primarily in the east, those other animals, just like any mammal, can contract rabies."

If another animal, like a dog, finds and eats the bait, it won't harm them.

Kirby thinks that with more resources, the U.S. could eradicate raccoon rabies in the coming decades.

But eradicating all rabies in the U.S. is a tall order.

Raccoons aren't the only reservoir. Skunks and bats also circulate the disease, with the latter being the leading cause of rabies deaths in people in the country.

Bats pose a particular challenge to any larger eradication effort.

How do you get an oral vaccine to an animal that flies?

Kirby says there have been some studies into aerosol vaccines or coating a few bats that will take it back to their colonies through grooming, "but it's still sort of in the infancy stages."

In the interim, Kirby says education around bats as rabies carriers is important. For example, knowing that people can't always feel a bat bite and that immediate treatment in the case of an exposure is the best tool for keeping people safe.

Further Reading:

Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts.

Curious about an infectious disease? Email us at shortwave@npr.org.

This episode was produced by Berly McCoy, edited by Rebecca Ramirezand fact checked by Anil Oza. Ko Takasugi-Czernowin was the audio engineer.

See the original post:

Plane-dropped bait vaccinates raccoons in the eastern U.S. : Short Wave - NPR

Right-wing figures try to blame Matthew Perry’s death on Covid vaccine – The Independent

November 2, 2023

Sign up to our Evening Headlines email for your daily guide to the latest news Sign up to our free US Evening Headlines email

Right-wing figures have claimed, without any evidence, that Matthew Perrys death was related to the actor being vaccinated for Covid-19.

The American-Canadian star, best known for his portrayal of sarcastic joker Chandler Bing in Friends, was found dead in his jacuzzi in the Pacific Palisades neighbourhood of Los Angeles on Saturday in an apparent drowning.

The 54-year-olds cause of death remains unclear, with an initial post-mortem coming back as inconclusive. A report released by the Los Angeles County Medical Examiners office said that the official cause of death is not likely to be declared for a few weeks.

But that did not stop a number of prominent right-wing anti-vax accounts from blaming Mr Perrys death on the Covid-19 vaccine.

Kandiss Taylor, a former Republican candidate for governor of Georgia and current GOP chair of Georgias first congressional district, was one of the people to make such a claim.

What??? Was he vaccinated? she wrote in response to news of his death on X.

Anti-vaxxers also allegedly edited Mr Perrys Wikipedia page to say, It is unclear whether the drowning was due to complications from the COVID-19 vaccine. The unfounded claim has since been deleted, the Rolling Stone reported.

Anti-vax accounts on X have previously falsely linked celebrity deaths to the Covid-19 vaccine.

In January, conspiracy theorists attempted to link the death of Elvis Presleys daughter Lisa Marie Presley to vaccines after she was found in cardiac arrest at her home, but X users were quick to condemn the comment.

Anyone attributing Lisa Marie Presley dying to the Covid vaccine is a f***ing moron, one person wrote.

Vaccines have been linked to heart problems such as Myocarditis, which can cause cardiac arrest, but it is extremely rare.

The Centers for Disease Control and Prevention (CDC) has estimated that between the ages of 18 and 29, it affects no more than 11.6 vaccinated young men per 100,000 that is, around 0.01 per cent.

Research has also shown that the risk of myocarditis is considerably higher from contracting Covid-19 than from getting vaccinated against it.

Ms Presley was later found to have died from a bowel obstruction caused by weight-loss surgery she had undergone several years before.

Conspiracy theories surrounding the death of Mr Perry came after he took the Covid-19 vaccine in May 2021.

The Friends actor previously detailed in his memoir his struggles with drug and alcohol addiction following his ascent to international stardom, aged 24.

The actors substance abuse began when he started drinking at the age of 14 before he became addicted to Vicodin, OxyContin, and Xanax, he revealed in his bestselling 2022 memoir, Friends, Lovers, and the Big Terrible Thing.

He said he first entered rehab in 1997, at the height of his Friends fame, after he became addicted to Vicodin following a jet-ski accident, and was admitted to rehab a further 14 times.

Friends star Matthew Perry has died aged 54

(AP Photo/Matt Sayles)

The actor also revealed he had 14 surgeries on his stomach due to gastrointestinal perforation stemming from his opioid abuse before his colon burst from excessive opioid use when he was 49.

He then spent two weeks in a coma and five months in the hospital. The doctors told my family that I had a 2 per cent chance to live, he wrote in his memoir.

I was put on a thing called an ECMO machine, which does all the breathing for your heart and your lungs. And thats called a Hail Mary. No one survives that, he added.

The actor estimated he spent $9m on his addiction battle.

Meanwhile, in late 2020, Mr Perry was forced to pull out of filming for Adam McKays climate change satire Dont Look Up after his heart stopped for five minutes.

In his memoir, he said his ribs had to be broken to resuscitate him.

Friends cast (from left) David Schwimmer, Jennifer Aniston, Courteney Cox, Matthew Perry, Lisa Kudrow, Matt LeBlanc.

(NBC)

Following his death, Mr Perrys family released a statement to People, saying: Matthew brought so much joy to the world, both as an actor and a friend. You all meant so much to him and we appreciate the tremendous outpouring of love.

Supporting actors from Friends also paid tribute to the 54-year-old.

Morgan Fairchild, who played Chandlers mother, Nora Bing, said: Im heartbroken about the untimely death of my son The loss of such a brilliant young actor is a shock.

Meanwhile, Maggie Wheeler, who played Chandlers love interest Janice, shared a picture of them together on Instagram with the caption: What a loss. The world will miss you Matthew Perry. The joy you brought to so many in your too short lifetime will live on. I feel so very blessed by every creative moment we shared.

Canadian prime minister Justin Trudeau, who was a friend of Perrys at school, called the stars death shocking and saddening. He wrote: Ill never forget the schoolyard games we used to play, and I know people around the world are never going to forget the joy he brought them. Thanks for all the laughs, Matthew. You were loved and you will be missed.

Read the original post:

Right-wing figures try to blame Matthew Perry's death on Covid vaccine - The Independent

Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs – CNBC

November 2, 2023

Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and the Covid vaccine.

Pfizer said it recorded a $5.6 billion charge for inventory write-offs in the third quarter due to lower-than-expected use of Covid products. Of these previously announced write-offs, $4.7 billion is chalked up to Paxlovid and $900 million is attributed to the company's vaccine.

The pharmaceutical giant also reiterated the full-year adjusted earnings and revenue guidance it announced two weeks ago, which is drastically lower than its initial projections due to weakening demand for its Covid products. That decline in demand also led Pfizer to announce a sweeping $3.5 billion cost-cutting plan at the same time.

Those efforts were seen as necessary to shore up investor sentiment as Pfizer and its rivals such as Moderna struggle to navigate the rapid decline of their Covid businesses, which are transitioning to the commercial market in the U.S. this year.

Here's what Pfizer reported for the third quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

Pfizer's stock closed flat Tuesday. Shares of Pfizer are down roughly 40% for the year, putting the company's market value at around $172 billion.

Pfizer reported third-quarter revenue of $13.23 billion, down 42% from the same period a year ago, due to the decline in sales of its Covid products.

The company's Covid vaccine raked in $1.31 billion in sales, down 70% from the year-ago quarter. Analysts had expected the shot to bring in $1.53 billion in sales, according to FactSet estimates.

Paxlovid posted $202 million in revenue, a drop of 97%. Analysts had expected $613.5 million in sales of the drug, according to FactSet estimates.

Together, the products pulled in around $1.5 billion in revenue for the quarter. That compares with roughly $12 billion in sales during the same period a year ago.

For the third quarter, Pfizer booked a net loss of $2.38 billion, or42 cents per share. That compares to a net income of $8.61 billion, or $1.51 per share, during the same period a year ago.

Excluding certain items, the company's loss per share was 17 cents for the quarter. The inventory write-offs of Covid products accounted for an 84 cent per share adjusted loss, Pfizer CFO David Denton said during an earnings call on Tuesday.

Pfizer reiterated the guidance it outlined in October: The company expects 2023 sales of $58 billion to $61 billion and full-year adjusted earnings of $1.45 to $1.65 per share.

The company anticipates that its Covid vaccine will rake in $11.5 billion in sales this year.

Meanwhile, the pharmaceutical giant expects its Covid antiviral treatment Paxlovid to bring in $1 billion in revenue. Pfizer has agreed to take eight million Paxlovid courses back early from the U.S. government, which is part of an effort to get more higher-priced sales of the drug on the commercial market.

Denton said 2023 will inform the company's expectations for vaccination rates and Covid product utilization rates in the U.S. next year.

Excluding Covid products, Pfizer said revenue for the quarter grew 10% operationally.

The company said that growth was partly fueled by its new vaccine against respiratory syncytial virus, which entered the market during the quarter for seniors and expectant mothers. The shot, known as Abrysvo, posted $375 million in sales for the period.

Pfizer is "really pleased" with the performance of Abrysvo, which exceeded the company's expectations, chief commercial officer Angela Hwang said during the earnings call.

She added that there is "very fast uptake" and Pfizer expects that momentum to continue.

CFOTO | Future Publishing | Getty Images

Recently acquired drugs also drove revenue. Biohaven Pharmaceuticals' migraine drug Nurtec ODT and Global Blood Therapeutics' sickle cell disease treatment Oxbryta drew in $233 million and $85 million, respectively.

The company said revenue was also fueled by strong sales of Vyndaqel drugs, which are used to treat a certain type of cardiomyopathy, a disease of the heart muscle. Those drugs booked $892 million in sales, up 48% from the third quarter of 2022.

A group of shots to protect against pneumococcal pneumonia also contributed, raking in $1.85 billion in sales for the quarter, up 15% from the year-ago period.

Meanwhile, Pfizer's blood thinner Eliquis posted $1.49 billion in revenue for the third quarter, up just 2% from a year ago. That came in slightly under analysts' estimates of $1.54 billion, according to FactSet.

Eliquis, which is marketed in partnership with Bristol Myers Squibb, is among the first 10 drugs to face Medicare drug price negotiations.

Wells Fargo analyst Mohit Bansal said in a research note Tuesday that the operational revenue growth during the quarter "bodes well" for Pfizer to meet its full-year guidance of 6% to 8% growth for non-Covid products compared to 2022.

Pfizer is hoping to shift investor focus away from Covid toward its growth opportunities, including mergers and acquisitions and a record pipeline.

Pfizer CEO Albert Bourla noted that the company is nearing its goal of launching 19 new products or drug indications in an 18-month span a target set last year.Indications refer to using a drug for a different disease type.

The company had a busy few months of product launches, which included a vaccine for RSV, an ulcerative colitis pill, a meningococcal vaccine and of course, the newest version of its Covid vaccine.That brings Pfizer to 13 out of 19 planned product launches.

Among the six remaining product launches is Pfizer's experimental flu vaccine, which it expects to launch after 2024. The company on Tuesday announced that its shot achieved positive initial results when compared to a currently marketed flu vaccine in an ongoing late-stage trial on people ages 18 to 64.

But investors are still waiting for more data on Pfizer's flu vaccine in adults 65 and older. People 65 years and older are at higher risk of developing serious complications from flu, compared with young, healthy adults. Between 70% and 85% of seasonal flu-related deaths in the U.S. occurred among people 65 years and older in recent years, according to the Centers for Disease Control and Prevention.

Investors are also waiting for updates on a midstage trial of Pfizer's oral obesity pill danuglipron, which could potentially compete with Eli Lilly's experimental obesity pill orforglipron. Positive data could solidify Pfizer as a viable competitor in the weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated.

Pfizer executives said that the company expects to close its $43 billion acquisition of cancer therapy maker Seagen in late 2023 or early 2024, subject to customary closing conditions such as clearance by the Federal Trade Commission.

The European Commission, the executive body of the European Union, already approved the proposed buyout earlier this month.

Pfizer continues to believe the deal could contribute more than $10 billion in risk-adjusted sales by 2030.

Don't miss these CNBC PRO stories:

The rest is here:

Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs - CNBC

How AI played an instrumental role in making mRNA vaccines – Big Think

November 2, 2023

For most of history, artificial intelligence (AI) has been relegated almost entirely to the realm of science fiction. Then, in late 2022, it burst into reality seemingly out of nowhere with the popular launch of ChatGPT, the generative AI chatbot that solves tricky problems, designs rockets, has deep conversations with users, and even aces the Bar exam.

But the truth is that before ChatGPT nabbed the publics attention, AI was already here, and it was doing more important things than writing essays for lazy college students. Case in point: It was key to saving the lives of tens of millions of people.

As Dave Johnson, chief data and AI officer at Moderna, told MIT Technology Reviews In Machines We Trust podcast in 2022, AI was integral to creating the companys highly effective mRNA vaccine against COVID. Moderna and Pfizer/BioNTechs mRNA vaccines collectively saved between 15 and 20 million lives, according to one estimate from 2022.

Johnson described how AI was hard at work at Moderna, well before COVID arose to infect billions. The pharmaceutical company focuses on finding mRNA therapies to fight off infectious disease, treat cancer, or thwart genetic illness, among other medical applications. Messenger RNA molecules are essentially molecular instructions for cells that tell them how to create specific proteins, which do everything from fighting infection, to catalyzing reactions, to relaying cellular messages.

Johnson and his team put AI and automated robots to work making lots of different mRNAs for scientists to experiment with. Moderna quickly went from making about 30 per month to more than one thousand. They then created AI algorithms to optimize mRNA to maximize protein production in the body more bang for the biological buck.

For Johnson and his teams next trick, they used AI to automate science, itself. Once Modernas scientists have an mRNA to experiment with, they do pre-clinical tests in the lab. They then pore over reams of data to see which mRNAs could progress to the next stage: animal trials. This process is long, repetitive, and soul-sucking ill-suited to a creative scientist but great for a mindless AI algorithm. With scientists input, models were made to automate this tedious process.

All these AI systems were in put in place over the past decade. Then COVID showed up. So when the genome sequence of the coronavirus was made public in January 2020, Moderna was off to the races pumping out and testing mRNAs that would tell cells how to manufacture the coronaviruss spike protein so that the bodys immune system would recognize and destroy it. Within 42 days, the company had an mRNA vaccine ready to be tested in humans. It eventually went into hundreds of millions of arms.

Moderna is now turning its attention to other ailments that could be solved with mRNA, and the company is continuing to lean on AI. Scientists are still coming to Johnson with automation requests, which he happily obliges.

We dont think about AI in the context of replacing humans, he told the Me, Myself, and AI podcast. We always think about it in terms of this human-machine collaboration, because theyre good at different things. Humans are really good at creativity and flexibility and insight, whereas machines are really good at precision and giving the exact same result every single time and doing it at scale and speed.

Moderna, which was founded as a digital biotech, is undoubtedly the poster child of AI use in mRNA vaccines. Moderna recently signed a deal with IBM to use the companys quantum computers as well as its proprietary generative AI, MoLFormer.

Modernas success is encouraging other companies to follow its example. In January, BioNTech, which partnered with Pfizer to make the other highly effective mRNA vaccine against COVID, acquired the company InstaDeep for $440 million to implement its machine learning AI across its mRNA medicine platform. And in May, Chinese technology giant Baidu announced an AI tool that designs super-optimized mRNA sequences in minutes. A nearly countless number of mRNA molecules can code for the same protein, but some are more stable and result in the production of more proteins. Baidus AI, called LinearDesign, finds these mRNAs. The company licensed the tool to French pharmaceutical company Sanofi.

Writing in the journal Accounts of Chemical Research in late 2021, Sebastian M. Castillo-Hair and Georg Seelig, computer engineers who focus on synthetic biology at the University of Washington, forecast that AI machine learning models will further accelerate the biotechnology research process, putting mRNA medicine into overdrive to the benefit of all.

More here:

How AI played an instrumental role in making mRNA vaccines - Big Think

Public encouraged to get Covid-19 and flu vaccines ahead of winter virus season ‘peak’ – TheJournal.ie

November 2, 2023

THE IRISH PUBLIC has been encouraged to take up their Covid-19 and flu vaccines ahead of the peak of winters virus season.

Thats the message from Chief Medical Officer (CMO) Professor Breda Smyth and Chief Nursing Officer (CNO) Rachel Kenna to all eligible persons following the commencement of the 2023/2024 influenza campaign.

The seasonalvaccinationprogramme will offer a fluvaccinein the form of a nasal spray for those aged 2-12, and an injectable fluvaccinefor all other eligible groups.

A Covid-19 booster vaccine is also available for those aged 50 and over, and certain other categories including those who are immunocompromised.

While the Department of Health said there has been a strong uptake for both vaccines to date, the CMO and CNO are reminding eligible persons to boost their protection before the respiratory virus season reaches its peak.

The two vaccines can be administered at the same time and are available through participating GPs and pharmacies, and in healthcare settings for healthcare workers.

The childrens nasal spray flu vaccine is also available to some primary school children within schools.

CMO Professor Breda Smyth said that along with good hand hygiene and respiratory etiquette, vaccines are the best way to protect ourselves from the respiratory illnesses circulating this winter.

Smyth said its very important that all those who are invited avail of their vaccines, describing it as a quick and easy way for people to protect their health, as well as protecting those around them.

Smyth also noted that young children are more likely to be very sick from flu and encouraged parents and guardians to consider getting their childvaccinated.

Meanwhile, CNO Rachel Kenna appealed to those in health and social care settings to getvaccinatedto protect themselves and vulnerable patients.

Walk-invaccination clinics for healthcare workers are operating around the country, with more details of these clinics available here.

The flu vaccine is available free of charge for everyone aged 65 and over, children aged 2 to 12, those who are pregnant, and to patients aged 6-23 months and 13-64 years at increased risk of flu-related complications.

Its also available free of charge to nursing home and other long stay facilities residents, healthcare workers, household contacts of people with underlying conditions or Down Syndrome, and out of home care givers.

Children who missed out on the fluvaccinein school can still get it through GPs and pharmacies.

Meanwhile, Covid-19 boosters are available for those aged 50 and older, those aged 5-49 with immunocompromise associated with a suboptimal response tovaccination, and those aged 5-49 years with medical conditions associated with a higher risk of Covid-19 hospitalisation, severe disease or death.

Its also available to health and care workersand pregnant persons, if it is more than six months since their previousvaccineor Covid-19 infection

Follow this link:

Public encouraged to get Covid-19 and flu vaccines ahead of winter virus season 'peak' - TheJournal.ie

Over 15 million Americans got updated COVID vaccines so far – Reuters

November 2, 2023

An exterior view of the United States Health and Human Services Building on C Street Soutwest in Washington, U.S., July 29, 2019. REUTERS/Tom Brenner/File Photo Acquire Licensing Rights

WASHINGTON, Nov 1 (Reuters) - Over 15 million people in the United States, around 4.5% of the population, had received the updated COVID-19 shots by Oct. 27, a Department of Health and Human Services (HHS) spokesperson said on Wednesday, lagging behind last year's vaccinations.

Close to 23 million people had received updated boosters as of Oct. 26 last year, U.S. Centers for Disease Control and Prevention (CDC) data shows. The 2022 fall vaccination campaign started around 10 days earlier than this year's.

"As of Oct. 27, more than 15 million Americans have received the updated COVID-19 vaccine and over 19 million vaccines have shipped to pharmacies and other locations, with 91% of Americans 12 years and older living within 5-miles of a vaccination site," the spokesperson said in an emailed statement.

The updated shots from Pfizer (PFE.N) and BioNTech (22UAy.DE), Moderna (MRNA.O) or Novavax (NVAX.O) are single-target vaccines aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for much of this year but has since been overtaken by other variants as the virus evolves.

Rollout of the Pfizer and Moderna shots began in earnest after the CDC recommended them on Sept. 12. The rollout of last year's updated shots targeting two virus variants started about 10 days earlier, and by Oct. 26, around 23 million Americans had rolled up their sleeves for one of them.

U.S. public health officials have expressed hope that Americans will welcome the new vaccines as they would an annual flu shot. But demand for COVID vaccines has dropped sharply since 2021, when they first became available.

Around 56.5 million people, or 17% of the U.S. population, received last year's version of the vaccines.

Reporting by Ahmed Aboulenein in Washington and Michael Erman in New York; Editing by Chizu Nomiyama and Aurora Ellis

Our Standards: The Thomson Reuters Trust Principles.

Washington-based correspondent covering U.S. healthcare and pharmaceutical policy with a focus on the Department of Health and Human Services and the agencies it oversees such as the Food and Drug Administration, previously based in Iraq and Egypt.

Excerpt from:

Over 15 million Americans got updated COVID vaccines so far - Reuters

Page 152«..1020..151152153154..160170..»